Abstract
Treatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. Clin Cancer Res; 21(24); 5415-6. ©2015 AACR.See related article by Peeters et al., p. 5469.
©2015 American Association for Cancer Research.
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Cetuximab
-
Colorectal Neoplasms / genetics
-
ErbB Receptors / genetics*
-
Humans
-
Mutation
-
Proto-Oncogene Proteins / genetics
-
ras Proteins / genetics*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Proto-Oncogene Proteins
-
ErbB Receptors
-
ras Proteins
-
Cetuximab